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INTRODUCTION
Delayed donor leukocyte infusions (DLI) after allogeneic
bone marrow transplantation (BMT) have induced dramatic
graft-versus-leukemia (GVL) effects in patients treated for
relapse of disease [1]. Despite the fact that DLI has been used
clinically for more than 10 years, the immune effector cells
involved in GVL reactivity have not been well characterized.
Both T cells and natural killer (NK) cells have been impli-
cated in GVL reactions after DLI [2-4]. The relative impor-
tance of these 2 cell populations likely depends on multiple
factors, including the genetic disparity between the donor and
recipient as well as the type of tumor targeted for therapy.
One of the more remarkable observations regarding
DLI therapy is that whereas graft-versus-host disease
(GVHD) is still a problem after DLI, less severe GVHD has
typically been observed in the posttransplantation setting
than would be anticipated if comparable numbers of donor
T cells were given at the time of BMT. The decreased risk
for developing severe GVHD after DLI has been attributed
to avoidance of conditioning-related toxicity [5,6], decreased
numbers of host antigen-presenting cells to stimulate
GVHD [7], and the reestablishment of immune regulatory
mechanisms that suppress T-cell alloreactivity [8]. In previ-
ous studies, we demonstrated that Thy1+ αβ T-cell receptor
(TCR)+ cells (CD4+8– and CD4–8–) suppress GVH reactivity
after DLI in mice [8]. We are currently investigating
whether other phenotypic markers can further distinguish
these immunosuppressive cells from nonsuppressive popula-
tions of T cells. NK T cells have been found to suppress
GVH reactivity [9,10], and they are comprised of cells
including αβTCR+CD4+ and αβTCR+CD4– cells [11].
Thus, the possibility exists that at least one subpopulation of
the Thy1+ αβTCR+ regulatory T cells identiﬁed in our pre-
vious studies is comprised of NK T cells.
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ABSTRACT
Donor regulatory T cells (CD3+ αβT-cell receptor [TCR]+) derived from the repopulating host thymus have been
shown to be primarily responsible for suppression of GVHD following DLI therapy in murine BMT models. How-
ever, natural killer (NK) T cells also have regulatory properties, and a role for NK T cells in suppression of GVH
reactivity has not been completely excluded. NK cells may also contribute to the graft-versus-leukemia (GVL) effect
associated with DLI therapy. In this study, we used a murine BMT model (C57BL/6 into AKR) to study whether
depletion of donor NK cells had any impact on the suppression of GVH reactivity after DLI or on the DLI-induced
GVL effect against acute T-cell leukemia. Depletion of donor NK cells was accomplished in vivo by giving DLI-
treated bone marrow chimeras multiple injections of anti-NK1.1 monoclonal antibody (MoAb). The chimeras
treated with anti-NK1.1 MoAb had significantly fewer splenic NK1.1+ cells than nontreated chimeras, and spleno-
cytes from anti-NK1.1–treated mice were deficient in the ability to generate lymphokine-activated lytic activity.
Results presented here showed that NK-cell depletion had no effect on the suppression of GVH reactivity after
DLI. When DLI-treated chimeras were challenged with an acute T-cell leukemia, NK-cell depletion had no dis-
cernible effect on GVL reactivity. These preclinical data suggest that donor NK cells do not have a significant role
in the suppression of GVHD after DLI or in the mediation of GVL reactivity induced by DLI.
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In the current study, we used a spontaneously arising
AKR leukemia as a model of acute T-cell leukemia to investi-
gate the role of donor NK cells in GVL and in the suppres-
sion of GVHD after DLI. Transplant recipients were treated
with an anti-NK1.1 monoclonal antibody (MoAb) to deplete
donor NK cells in vivo. Donor NK cells did not contribute
to the GVL effect of DLI against this tumor. In vivo deple-
tion of NK1.1+ cells also did not increase the severity of
GVHD, indicating that CD4+ or CD4– NK T cells do not
play a role in the suppression of GVH reactivity after DLI.
MATERIALS AND METHODS
Mice
AKR/J (H-2k, Thy1.1, NK1.1–), C57BL/6 (H-2b,
Thy1.2, NK1.1+), and B6.PL-Thy1a (H-2b; Thy1.1+) mice
were obtained from Jackson Laboratories (Bar Harbor, ME)
at 4 to 6 weeks of age. The animals were cared for in the
Medical College of Wisconsin Animal Resource Center,
which is accredited by the American Association for the
Accreditation of Laboratory Animal Care.
Leukemia
The tumor used in these studies is an acute T-cell
leukemia that spontaneously arose in a male AKR mouse.
The leukemia, designated as M2, was passaged in vivo, har-
vested from the spleens of inoculated AKR mice, and frozen
as a stock. Vials of the frozen stock were thawed for
leukemia-challenge experiments, and the same stock of
leukemia was used to minimize experimental variability. The
leukemia is CD4+, variable for CD8 expression, Thy1.1+,
major histocompatibility complex (MHC)-class I+, MHC-
class II–, CD3+, and TCR Vβ6+.
Experimental Design
The basic experimental design used to assess the effect
of donor NK-cell depletion on GVL and GVH reactions
after DLI is shown in Figure 1. AKR recipients were pre-
conditioned for BMT with a lethal dose of total body irra-
diation (1100 cGy) from a cesium source. Twenty-four
hours after irradiation, BM was collected from C57BL/6
donor mice by flushing collected femurs and tibias with
Dulbecco’s modified Eagle’s medium (DMEM) culture
medium. The BM cells were treated with anti-Thy1.2
MoAb (clone 30-H12; American Type Culture Collection,
Rockville, MD) and Low-Tox-M complement (Accurate
Chemical and Scientiﬁc, Westbury, CT) to remove T cells.
The irradiated AKR recipients were administered trans-
plants by intravenous (IV) injection with 107 C57BL/6
T-cell–depleted BM cells.
For in vivo donor NK-cell depletion, BM chimeras were
treated intraperitoneally (IP) with anti-NK1.1 MoAb (clone
PK 136; ATCC) beginning on day 24 after BMT, for a total
of 6 to 10 injections (500 µg per injection). Speciﬁcally, anti-
NK1.1 MoAb was given on days 24, 26, 30, 32, 36, and 38
for a total of 6 injections or with additional injections on
days 42, 44, 48, and 52 for a total of 10 injections. In some
experiments, mice were depleted in vivo of Thy1.2+ cells by
treating BM chimeras with IP injections of anti-Thy1.2
MoAb (clone 30-H12) on days 24 and 26 after BMT.
DLI was given on day 28 after BMT as a single IV
injection of 3 × 107 C57BL/6 or Thy1 congenic B6.PL-
Thy1a spleen cells. GVH reactivity is significantly sup-
pressed when DLI is given at this time point in the
C57BL/6-into-AKR model [8].
Due to the aggressiveness of the AKR M2 leukemia,
mice were challenged with different doses of leukemia after
DLI. This same tumor-challenge approach has been used in
previous studies to assess GVL reactivity [12,13]. BM
chimeras were injected IV on day 35 after BMT with indi-
cated numbers of M2 leukemia cells.
Phenotypic Analysis and Cytolytic Assays
To assess the effectiveness of in vivo NK-cell depletion,
splenocytes of individual anti-NK1.1 treated and nontreated
BM chimeras were collected on day 28 or day 56 after BMT.
Red cells were eliminated by hypotonic lysis. The cells were
stained with a combination of anti–CD3-ﬂuorescein isothio-
cyanate and anti–NK1.1-phycoerythrin MoAbs (BD
PharMingen, San Diego, CA) and analyzed by ﬂow cytome-
try to determine the percentages of NK1.1+ cells. For each
sample, 5 × 104 events were collected for analysis.
Effectiveness of NK-cell depletion was confirmed by
performing NK/lymphokine-activated killer (LAK) cytolytic
assays as previously described [14]. Brieﬂy, splenocytes col-
lected for phenotypic analysis were cultured for 3 days in
complete DMEM [15] containing 10% fetal bovine serum
(FBS) and 500 U/mL human recombinant interleukin (IL)-2
(ID Labs Inc, London, Ontario, Canada). Following culture,
the cells were washed twice with DMEM by centrifugation,
resuspended in complete DMEM containing 5% FBS,
counted, and placed in quadruplicate U-bottom microtiter
wells with 2500 51Cr-labeled NK/LAK-sensitive YAC-1
murine lymphoma cells at effector:target ratios ranging
from 200:1 to 6:1. The effector and target cells were cocul-
tured for 3 hours, then supernatants were collected from
each well for γ scintillation counting. Maximum and sponta-
neous release values were obtained by culturing target cells
alone in detergent or culture medium, respectively. The
percent lysis was calculated by the following formula:
cpm experimental – 
% lysis (chromium release) = cpm spontaneous release × 100cpm maximum release –
cpm spontaneous release
Statistics
Survival curves were compared using the log-rank test.
The percentages of NK1.1+ splenocytes, spleen and thymus
Figure 1. Experimental design to address whether donor-derived NK
cells affect GVL and GVH reactions after DLI in MHC-mismatched
BM chimeras.
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cell numbers, and percentages of splenic B cells were com-
pared using the Student t test.
RESULTS
Treatment of BM Chimeras With Anti-NK1.1 MoAb
Significantly Depleted NK Cells In Vivo
To assess the effectiveness of NK1.1-cell depletion in
anti-NK1.1–treated mice, BM chimeras were euthanized
after the ﬁrst 2 injections of anti-NK1.1 MoAb (day 28 after
BMT) as well as after the final injection of a 10-injection
treatment regimen (day 56 after BMT). Individual spleens
were processed into single-cell suspensions and analyzed for
engraftment status and NK1.1+ cell content. In this model,
by day 28 after BMT the lethally conditioned recipients are
fully engrafted with donor cells, except for the T-cell com-
partment, which contains 10% to 20% residual host T cells
(data not shown). Treatment with DLI eliminated the resid-
ual host T cells by 2 weeks after infusion. As shown in the
Table, the spleens of anti-NK1.1–treated chimeras on days
28 and 56 after BMT had significantly lower percentages
and absolute numbers of NK1.1+ cells than the spleens of
nontreated chimeras. Small percentages of NK1.1/CD3
double-positive cells (0.2%-0.3% of total splenocytes) were
seen in the spleens of nontreated chimeras and, similarly,
these cells were also depleted to nearly undetectable levels
(< 0.1%) in anti-NK1.1–treated chimeras (data not shown).
Interestingly, the spleens of day 56 non–antibody-treated
chimeras previously given a DLI also had signiﬁcantly fewer
NK1.1+ cells than non–antibody-treated chimeras that
received transplants of BM only (Table). However, absolute
numbers of splenic NK1.1+ cells in these mice were still
signiﬁcantly higher than those in anti-NK1.1–treated mice.
Splenocytes from the chimeras analyzed for NK1.1-cell
content were also tested for the ability to generate NK/LAK
cytolytic activity after culture with IL-2. This approach was
used because NK-cell activity in freshly isolated mouse
splenocytes is difficult to detect, and we previously found
that the ability to generate LAK activity is directly associ-
ated with NK-cell content [14]. Splenocytes isolated from
anti-NK1.1–treated chimeras on both day 28 and day 56
after BMT generated significantly lower NK/LAK lytic
activity than splenocytes from nontreated chimeras (Figure 2),
confirming the phenotypic data in the Table. Splenocytes
from DLI-treated chimeras on day 56 after BMT, which
contained signiﬁcantly lower numbers of NK1.1+ cells than
non-DLI–treated chimeras (Table), also generated lower
NK/LAK lytic activity than did splenocytes from non-
DLI–treated chimeras (Figure 2B).
NK T Cells Do Not Play a Role in the Suppression of
GVH Reactivity After DLI
A series of experiments was done to assess whether
donor NK1.1+ cells suppress GVH reactivity after DLI. Two
previous observations led us to undertake these experiments.
First, NK cells have been shown to contribute to GVH reac-
tivity after allogeneic BMT [14,16]. Second, NK T cells have
been shown by others to be immunosuppressive [17], and in
the current studies we detected small percentages (0.2%-
0.3%) of NK T cells (NK1.1/CD3 double positive) in the
spleens of BM chimeras (data not shown). We have previ-
ously demonstrated that there are populations of thymus-
derived Thy1+ αβTCR+ regulatory cells that suppress GVH
reactivity after DLI [8]. Thus, T cells expressing the NK1.1
antigen were candidates for regulatory T cells in our model.
For these experiments, BM chimeras given a DLI were
treated with a 6-injection regimen (days 24-38 after BMT)
of anti-NK1.1 MoAb (Figure 3). For comparison, 2 other
groups of BM chimeras were included in these experiments.
One group was given DLI with no anti-NK1.1 MoAb. His-
torically, these mice have developed relatively mild GVHD
[8]. A second group was treated with in vivo–depleting anti-
Thy1.2 MoAb prior to DLI to eliminate donor regulatory
T cells. This group was included in the experiment to
demonstrate that DLI can induce severe GVHD if immuno-
regulatory T cells are eliminated [8]. For DLI treatment
in these experiments, B6.PL-Thy1a spleen cells (Thy1.1+)
were given so that the infused donor T cells would not
be depleted by residual MoAb in anti-Thy1.2–treated
chimeras. If NK1.1+ T cells function as regulatory T cells
after DLI, we anticipated that GVHD would be more
severe in anti-NK1.1–treated chimeras than in nontreated
chimeras. However, survival of the NK1.1-depleted chimeras
was not significantly different from that of non–NK1.1-
depleted chimeras (Figure 3A). Body weight curves of these
2 groups were also similar (P > .05) (Figure 3B). All 3 groups
In Vivo Treatment of BM Chimeras with Anti-NK1.1 MoAb Resulted in a Signiﬁcant Depletion of NK1.1+ Splenocytes
Absolute No. of
Day Post-BMT n Treatment* % NK1.1+ Splenocytes (±SD) NK1.1+ Cells, ×105 (±SD)
28 10 BM 1.6 (±0.5) 11.80 (±6.27)
10 BM/Anti-NK1.1 0.3 (±0.2)† 2.14 (±1.36)†
56 5 BM only (no DLI) 1.0 (±0.1) 9.04 (±0.88)
5 DLI 0.4 (±0.2)‡ 2.15 (±1.05)‡
5 Anti-NK1.1/DLI 0.2 (±0.1)‡ 0.77 (±0.34)‡§
*B6/AKR BM chimeras were treated or not treated with anti-NK1.1 MoAb (see “Materials and Methods” for details). Some chimeras were given
DLI on day 28 after BMT, as indicated. Mice were killed for analysis on either day 28 or day 56 after BMT (ie, 2 days after the second anti-NK1.1
MoAb injection or 4 days after the last of 10 injections, respectively). Percentages and absolute numbers of splenic NK1.1+ cells were determined by
ﬂow cytometric analysis. The data are the combined results of 3 sets of experiments.
†P < .05 compared with day 28 non–anti-NK1.1–treated chimeras.
‡P < .05 compared with day 28 non–anti-NK1.1–treated chimeras receiving BM transplants only (no DLI).
§P < .05 compared with day 56 DLI-treated chimeras.
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of BM chimeras lost body weight during the ﬁrst 2 weeks
after DLI. Whereas body weights of the anti-NK1.1–treated
and nontreated chimeras plateaued, the Thy1.2-depleted
chimeras continued to lose body weight and died. Similar
results were obtained in experiments in which the 10-injection
regimen of anti-NK1.1 MoAb was used (data not shown).
These data indicated that donor NK cells are not involved
in the suppression of GVH reactivity after DLI.
Depletion of Donor NK Cells In Vivo Did Not Alter
the DLI-Induced GVL Effect Against a T-Cell Leukemia
To examine whether donor NK-cell depletion in vivo
had an effect on GVL reactivity induced by DLI, the fol-
lowing 3 groups of BM chimeras were challenged with 102,
103, or 104 AKR M2 leukemia cells: (a) a group given BM
only (no DLI), (b) a group treated with DLI, and (c) a group
treated with anti-NK1.1 MoAb and DLI. For anti-NK1.1
MoAb treatment, the mice were given a 10-injection regi-
men (days 24-52 after BMT) to encompass the time period
during which mice that received transplants with T-cell–
depleted BM begin to die of tumor progression after chal-
lenge [12]. DLI was given on day 28 after BMT and challenge
with leukemia 1 week later (day 35). AKR recipients of
T-cell–depleted BM only (no DLI) died of tumor progres-
sion, with the exception of 2 mice challenged with 103
leukemia cells (Figure 4). Thus, the lethal dose for this
leukemia in AKR mice that received transplants with B6 BM
is fewer than 102 cells. Treatment with DLI induced a
significant GVL effect, as indicated by long-term survival
rates of ≥75% at all 3 doses of leukemia (Figure 4). Based on
observations made at necropsy, the majority of deaths in
these mice were attributed to GVH reactivity and not tumor
progression. At all 3 doses of leukemia, the overall survival
of NK1.1-depleted chimeras given DLI was not signifi-
cantly different from that of nondepleted chimeras given
DLI (Figure 4), indicating that treatment of BM chimeras
with anti-NK1.1 MoAb had no impact on GVL reactivity.
DISCUSSION
In the current study, we investigated the role of donor
NK cells in suppression of GVHD after DLI and whether
depletion of NK cells altered DLI-induced GVL reactivity
against a murine T-cell leukemia. To eliminate donor-
derived NK cells in vivo, a MoAb directed to the NK1.1
antigen (clone PK136) was employed [18]. NK1.1+ cells
were signiﬁcantly depleted after in vivo treatment with anti-
NK1.1 MoAb, and the elimination of donor NK cells did
not affect suppression of GVHD after DLI or have a dis-
cernible impact on DLI-induced GVL reactivity.
We were interested in looking at the effect of NK1.1
depletion on GVH reactivity after DLI to determine whether
immunoregulatory cells that suppress GVH reactivity after
DLI [8] express the NK1.1 antigen. At least 2 populations of
Thy1+ αβTCR+ cells (CD4+ 8– and CD4–8–) play important
roles in the suppression of GVH reactivity after DLI [8].
Immunosuppressive NK1.1+ T cells expressing these same
markers have been described by others and have been shown
to suppress GVH reactivity both vitro and in vivo [9,10].
These observations led us to investigate whether NK1.1+ cells
play a role in the suppression of GVH reactivity after DLI.
The data indicated that cells expressing the NK1.1 antigen do
not have any role in the suppression of DLI-induced GVH
reactivity (Figure 3 and data not shown). These results have
led us to focus our efforts on looking at other cell surface
markers, such as CD25, to further distinguish the Thy1+
αβTCR+ regulatory T cells from other T cells.
Figure 2. Splenocytes isolated from BM chimeras treated with anti-
NK1.1 MoAb show minimal lytic activity after culture with high-dose
IL-2. AKR recipients were transplanted with B6 BM, then randomized
to receive no further treatment (BM only) or DLI with 3 × 107 B6 donor
spleen cells at 28 days post-BMT. Some chimeras were treated with anti-
NK1.1 MoAb starting on day 24 post-BMT (see “Materials and Meth-
ods” for details). Splenocytes were isolated from anti-NK1.1–treated and
untreated BM chimeras (A) on day 28 after BMT (day of DLI), or (B)
day 56 after BMT (4 days after the last MoAb treatment). The spleno-
cytes were cultured with IL-2 for 3 days, then assayed for lytic activity
versus YAC-1 targets. The lytic curves are from 2 or 3 individual and
representative mice per group taken from 3 sets of experiments.
NK Cells and DLI
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Similar to the clinical data from Jiang and coworkers [4],
suppressed NK function as well as reduced numbers of NK
cells were observed in mouse BM chimeras given DLI (Fig-
ure 2B and Table). We did not look at NK-cell function past
day 56 after BMT, but at approximately 100 days after BMT
mice given DLI had significantly reduced numbers of
NK1.1+ cells compared to mice not given a DLI (data not
shown). Because similar reduced numbers of NK cells were
observed in both anti-NK1.1–treated and nontreated mice,
it appears that the DLI treatment had a long-term effect on
NK1.1+-cell numbers. The biologic signiﬁcance of reduced
splenic NK-cell numbers, if any, is not known.
Due to the relatively mild GVH reactivity in the DLI
model used for these studies, we were unable to assess the
role of NK cells as GVH effectors after DLI. For this
assessment, a DLI model in which stronger GVH reactivity
occurs would be needed. Perhaps a model in which regula-
tory T cells have been depleted to allow for the develop-
ment of GVHD after DLI could be employed to study the
role of NK cells as GVH effectors.
Donor T cells are essential mediators in the GVL effect
against AKR T-cell leukemias after DLI [12]. Thus, it is not
surprising that donor NK cells did not play a signiﬁcant role
in the GVL effect against an aggressively growing acute
T-cell leukemia (Figure 4). Our results confirm previous
work by Blazar et al. [19], who showed that NK cells were
not the major DLI-induced GVL effectors against either
EL4, another murine T-cell leukemia, or C1498, a murine
acute myeloid leukemia. However, because others have
demonstrated that NK cells can mediate GVL reactions
Figure 3. Depletion of donor NK cells did not signiﬁcantly affect GVH reactivity after DLI. Irradiated AKR recipients received transplants of
107 B6 BM cells. Indicated groups of recipients were treated with anti-Thy1.2 MoAb or anti-NK1.1 MoAb. Anti-Thy1.2 MoAb was given on days 24
and 26 post-BMT, and anti-NK1.1 MoAb was given as 6 injections over a 2-week period starting on day 24 (see “Materials and Methods” for
details). All recipients were given DLI at 28 days after BMT, with 3 × 107 B6.PL-Thy1a spleen cells. The mice were followed for (A) survival and (B)
body weight changes. Survival curves are the combined data of 3 experiments, and the body weight curves are from 1 representative experiment.
B.D. Johnson et al.
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after allogeneic BMT [20,21] as well as after DLI [22], the
role of NK cells in the GVL effect after DLI may depend
on the type of tumor or other unknown factors. The AKR
leukemia used in our studies is highly aggressive, with a
lethal dose of less than 100 cells. Because the DLI inoculum
used in our studies contained fewer than 106 donor NK cells
(data not shown), it appeared unlikely that these relatively
small numbers of DLI-derived NK cells would contribute to
GVL reactivity. Rather, we anticipated that any contribution
of NK cells to a GVL effect would originate from the endo-
genous donor NK cells. Perhaps greater numbers of adop-
tively transferred NK cells or treatment with IL-2–activated
NK cells might enhance NK-mediated GVL reactivity in
our model, as suggested by data from other investigators
[23-25]. In other studies, we generated data suggesting that
NK cells can negatively inﬂuence GVL reactions after allo-
geneic BMT [26]. Due to the strength of DLI-induced
GVL reactivity, experiments in the current study could not
assess whether donor NK cells may actually suppress GVL
reactivity after DLI.
In the clinical setting, the contribution of NK cells to
GVL reactivity after DLI has been unclear. T cells are
important to the GVL effect, but it is not known whether
NK cells can contribute to the elimination of tumor cells
after DLI, or perhaps even suppress GVL reactions after
DLI. Relatively high numbers of NK cells have been found
in the peripheral blood of patients early after allogeneic
BMT [2,27], suggesting that these cells would be present at
the time of DLI to potentially mediate a GVL effect. Jiang
et al. investigated immune function in 2 patients who
achieved complete remission after DLI for the treatment of
relapsed chronic myeloid leukemia, and they found that
there was a period of depressed NK-cell function, which
eventually recovered [4]. Interestingly, the recovery of NK
function coincided with the disappearance of disease, sug-
gesting that NK cells may have been involved in the GVL
effect. However, the true role that NK cells play in GVL
reactions after DLI in humans continues to be unknown.
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